Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET) has announced the acceptance of a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation will focus on the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma. The presentation will be given by Dr. Monica Moreno on December 10, 2023, from 6:00 - 8:00 p.m. PDT.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced the acceptance of a poster presentation at the upcoming 65^th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, CA from December 9-12, 2023.

Details of the poster presentation are as follows:

Title: Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma
Poster Number: 3478
Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II
Presenting Author: Monica Moreno, Ph.D.
Date/Time: Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231102190660/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What is the company name mentioned in the press release?

The company mentioned in the press release is Adicet Bio, Inc.

What is the ticker symbol of Adicet Bio, Inc.?

The ticker symbol of Adicet Bio, Inc. is ACET.

What is the focus of Adicet Bio, Inc.?

Adicet Bio, Inc. is a clinical stage biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer.

What is the upcoming event mentioned in the press release?

The upcoming event mentioned in the press release is the 65th American Society of Hematology (ASH) Annual Meeting.

What will be the topic of the poster presentation?

The topic of the poster presentation will be the expansion, persistence, and pharmacodynamic profile of ADI-001, a first-in-class allogeneic CD20-targeted CAR Gamma Delta T cell therapy, in patients with relapsed/refractory aggressive B-cell non-Hodgkin's lymphoma.

Who will be the presenting author of the poster presentation?

The presenting author of the poster presentation will be Dr. Monica Moreno, Ph.D.

When and where will the poster presentation take place?

The poster presentation will take place on Sunday, December 10, 2023, from 6:00 - 8:00 p.m. PDT at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, CA.